GoodRx Holdings, Inc. (NASDAQ:GDRX - Get Free Report) gapped up before the market opened on Tuesday . The stock had previously closed at $4.11, but opened at $4.26. GoodRx shares last traded at $4.46, with a volume of 627,638 shares traded.
Analyst Upgrades and Downgrades
GDRX has been the subject of a number of recent analyst reports. The Goldman Sachs Group lowered their target price on shares of GoodRx from $6.00 to $5.00 and set a "neutral" rating for the company in a research note on Friday, May 9th. UBS Group lowered their target price on shares of GoodRx from $6.00 to $5.25 and set a "neutral" rating for the company in a research note on Tuesday, May 13th. Wells Fargo & Company lowered their target price on shares of GoodRx from $8.00 to $7.00 and set an "overweight" rating for the company in a research note on Tuesday, April 29th. Finally, Truist Financial lowered their target price on shares of GoodRx from $6.50 to $5.50 and set a "hold" rating for the company in a research note on Thursday, April 10th. Five investment analysts have rated the stock with a hold rating, five have assigned a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat.com, GoodRx presently has a consensus rating of "Moderate Buy" and an average price target of $6.55.
Read Our Latest Report on GDRX
GoodRx Price Performance
The company has a debt-to-equity ratio of 0.70, a current ratio of 5.48 and a quick ratio of 5.48. The firm has a fifty day moving average of $4.25 and a two-hundred day moving average of $4.53. The stock has a market capitalization of $1.62 billion, a P/E ratio of -151.00, a P/E/G ratio of 2.46 and a beta of 1.16.
GoodRx (NASDAQ:GDRX - Get Free Report) last released its quarterly earnings data on Wednesday, May 7th. The company reported $0.09 earnings per share for the quarter, beating the consensus estimate of $0.04 by $0.05. The firm had revenue of $202.97 million during the quarter, compared to the consensus estimate of $202.25 million. GoodRx had a positive return on equity of 5.35% and a negative net margin of 2.05%. The firm's quarterly revenue was up 2.6% on a year-over-year basis. During the same period in the previous year, the company posted $0.08 earnings per share. On average, analysts predict that GoodRx Holdings, Inc. will post 0.13 EPS for the current year.
Insider Activity at GoodRx
In other GoodRx news, major shareholder Equity Vii L.P. Spectrum sold 10,677 shares of the business's stock in a transaction dated Friday, June 6th. The shares were sold at an average price of $4.09, for a total value of $43,668.93. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. 4.53% of the stock is currently owned by corporate insiders.
Hedge Funds Weigh In On GoodRx
A number of large investors have recently added to or reduced their stakes in GDRX. 8 Knots Management LLC bought a new position in GoodRx in the first quarter worth about $8,106,000. Clearbridge Investments LLC bought a new position in GoodRx in the fourth quarter worth about $5,863,000. EVR Research LP raised its holdings in GoodRx by 243.3% in the first quarter. EVR Research LP now owns 1,300,000 shares of the company's stock worth $5,733,000 after purchasing an additional 921,337 shares in the last quarter. Jacobs Levy Equity Management Inc. raised its holdings in GoodRx by 303.3% in the fourth quarter. Jacobs Levy Equity Management Inc. now owns 1,061,461 shares of the company's stock worth $4,936,000 after purchasing an additional 798,261 shares in the last quarter. Finally, Raymond James Financial Inc. acquired a new position in shares of GoodRx during the fourth quarter valued at about $2,500,000. 63.77% of the stock is currently owned by institutional investors.
About GoodRx
(
Get Free Report)
GoodRx Holdings, Inc, together with its subsidiaries, offers information and tools that enable consumers to compare prices and save on their prescription drug purchases in the United States. The company operates a price comparison platform that provides consumers with curated, geographically relevant prescription pricing, and access to negotiated prices.
Recommended Stories
Before you consider GoodRx, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and GoodRx wasn't on the list.
While GoodRx currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Thinking about investing in Meta, Roblox, or Unity? Enter your email to learn what streetwise investors need to know about the metaverse and public markets before making an investment.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
